HCP Live

Novel treatments in pipeline for diabetic eye disease

Article
Conference|AAO

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.


Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Related Videos
Related Content
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

April 19th 2024
Article
Integrating AI to manage DR in a primary care setting

Integrating AI to manage DR in a primary care setting

December 1st 2020
Podcast
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

April 14th 2024
Article
What to expect from virtual AAO 2020

What to expect from virtual AAO 2020

November 5th 2020
Podcast
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

April 10th 2024
Article
Clinical trials: Companies tackle AMD in early 2024

Clinical trials: Companies tackle AMD in early 2024

April 2nd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.